The intestinal micro-ecosystem, as the largest, most important, and most complex system in the human body, plays an extremely significant role. Intestinal flora is closely associated with liver cirrhosis. Gut-derived pathogen-associated molecular patterns (PAMPs)such as lipopolysaccharide (LPS) act as activators of liver macrophages and play a role in liver inflammation and fibrosis. The decomposition of urea by intestinal enzyme-producing bacteria can lead to hyperammonemia and hepatic encephalopathy (HE), a serious complication of liver cirrhosis. This is also the manifestation of the gut-liver-brain axis in hepatic encephalopathy. Fecal microbiota transplantation (FMT) can alter the composition and function of intestinal microbiota. Probiotics and antibiotic treatment can also regulate intestinal microbiota and reduce endotoxemia, thereby improving hepatic encephalopathy through the gut-liver-brain axis. Moreover, multi-omics techniques were used to explore specific biomarkers for patients with cirrhosis at the gene and functional levels, to analyze the changes of intestinal microbial diversity, and to explore the regulatory mechanism of intestinal microecological imbalance by fecal bacteria transplantation, probiotics and symbiosis. The study of the relationship between intestinal microbiota and cirrhosis can provide clinical value for its prevention, treatment and prognosis.
This Research Topic encourages authors to submit Original Research or Review articles related to human intestinal microecology and the development of cirrhosis, focusing on the early non-invasive diagnosis of cirrhosis and its development as a new therapeutic target. In addition, we particularly welcome authors to publish unique views on human microbiology, providing a new perspective for review articles.
We welcome papers from researchers in the fields of the following themes:
• Dynamic changes and correlative mechanisms of gut microbiota during the occurrence and development of cirrhosis;
• Microbiota characteristics of cirrhosis patients with different etiologies and other comorbidities;
• Characteristics of intestinal microecology in patients with hepatocellular carcinoma induced by cirrhosis;
• The role of intestinal microbiota in different prognostic outcomes of cirrhosis;
• Evaluation and mechanism of the metabolic network between the microbiome and liver cirrhosis hosts;
• Study on the relationship and related mechanism of human microecology in immune and endocrine aspects in patients with liver cirrhosis;
• Bacterial translocation, inflammation, and infection in cirrhosis;
• The mechanism of gut-liver-brain axis in liver cirrhosis;
• The intervention of probiotics or synbiotics on the prevention and treatment of cirrhosis and the related mechanism;
• New ways or techniques to discover links between microbiology and liver cirrhosis.
The intestinal micro-ecosystem, as the largest, most important, and most complex system in the human body, plays an extremely significant role. Intestinal flora is closely associated with liver cirrhosis. Gut-derived pathogen-associated molecular patterns (PAMPs)such as lipopolysaccharide (LPS) act as activators of liver macrophages and play a role in liver inflammation and fibrosis. The decomposition of urea by intestinal enzyme-producing bacteria can lead to hyperammonemia and hepatic encephalopathy (HE), a serious complication of liver cirrhosis. This is also the manifestation of the gut-liver-brain axis in hepatic encephalopathy. Fecal microbiota transplantation (FMT) can alter the composition and function of intestinal microbiota. Probiotics and antibiotic treatment can also regulate intestinal microbiota and reduce endotoxemia, thereby improving hepatic encephalopathy through the gut-liver-brain axis. Moreover, multi-omics techniques were used to explore specific biomarkers for patients with cirrhosis at the gene and functional levels, to analyze the changes of intestinal microbial diversity, and to explore the regulatory mechanism of intestinal microecological imbalance by fecal bacteria transplantation, probiotics and symbiosis. The study of the relationship between intestinal microbiota and cirrhosis can provide clinical value for its prevention, treatment and prognosis.
This Research Topic encourages authors to submit Original Research or Review articles related to human intestinal microecology and the development of cirrhosis, focusing on the early non-invasive diagnosis of cirrhosis and its development as a new therapeutic target. In addition, we particularly welcome authors to publish unique views on human microbiology, providing a new perspective for review articles.
We welcome papers from researchers in the fields of the following themes:
• Dynamic changes and correlative mechanisms of gut microbiota during the occurrence and development of cirrhosis;
• Microbiota characteristics of cirrhosis patients with different etiologies and other comorbidities;
• Characteristics of intestinal microecology in patients with hepatocellular carcinoma induced by cirrhosis;
• The role of intestinal microbiota in different prognostic outcomes of cirrhosis;
• Evaluation and mechanism of the metabolic network between the microbiome and liver cirrhosis hosts;
• Study on the relationship and related mechanism of human microecology in immune and endocrine aspects in patients with liver cirrhosis;
• Bacterial translocation, inflammation, and infection in cirrhosis;
• The mechanism of gut-liver-brain axis in liver cirrhosis;
• The intervention of probiotics or synbiotics on the prevention and treatment of cirrhosis and the related mechanism;
• New ways or techniques to discover links between microbiology and liver cirrhosis.